The company’s trial of Haduvio met its primary and secondary endpoints in reducing coughing fits across patients by 53%.

GlobalData predicts that icotrokinra will reach blockbuster status in 2029, with the drug forecast to generate sales of ...

CervoMed has announced positive results from the extension phase 2b RewinD-LB study of neflamapimod for dementia with Lewy ...

Protagonist Therapeutics (PTGX) announced topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...

Explore SGMT's breakthrough MASH therapy, Denifanstat, with FDA designation & Phase 3 progress. Click here to read my most ...

Enrollment completed in VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC); topline data expected ...

REHOVOT, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: ...

"The SGR is a transformative project for Kisumu and the entire western Kenya region. This extension will bring much-needed ...

The AHFIRM trial did not demonstrate a beneficial effect of larsucosterol on 90-day mortality or the need for liver transplant among patients with severe alcohol-associated hepatitis, or AH, according ...

Beckley Psytech has completed subject enrolment for the core stage of the global Phase IIb clinical trial of patent-protected ...

Investor Conferences. VYNE will be participating in the upcoming Leerink Partners Global Healthcare Conference, taking place in Miami from March 10-12, 2025, as well as the H.C. Wainwright 3rd Annual ...